Monjuvi

• Monjuvi is a CD19-directed cytolytic antibody used to treat certain types of diffuse large B-cell lymphoma (DLBCL).
• It works by targeting a protein on the surface of cancerous B-cells, leading to their destruction.
• The medication is administered intravenously in combination with lenalidomide.
• Common side effects include fatigue, diarrhea, cough, and fever.
• It is typically prescribed for adult patients whose disease has returned or is resistant to other therapies.

What is Monjuvi?

Monjuvi (tafasitamab-cxix) is a monoclonal antibody designed to target and destroy cancerous B-cells. It is specifically approved for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from low-grade lymphoma, who are not eligible for autologous stem cell transplant. This medication is administered intravenously in combination with another drug, lenalidomide.

As a key piece of Monjuvi drug information, it is important to understand that this medication functions by binding to the CD19 protein, which is found on the surface of B-cells, including malignant lymphoma cells. This binding initiates a process that leads to the destruction of these cancer cells, offering a targeted approach to treatment.

What Monjuvi Treats and How It Works

Monjuvi is primarily used to treat diffuse large B-cell lymphoma (DLBCL), a fast-growing type of non-Hodgkin lymphoma. According to the American Cancer Society, non-Hodgkin lymphoma is one of the most common cancers in the United States, accounting for about 4% of all cancers. DLBCL is the most common subtype, representing about 1 in 3 cases of non-Hodgkin lymphoma.

The mechanism by which Monjuvi treats lymphoma involves its specific interaction with the CD19 protein. Once Monjuvi binds to CD19 on the surface of lymphoma cells, it recruits immune effector cells to the tumor site. These immune cells then work to destroy the cancerous B-cells through various mechanisms, including antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). This targeted action helps to reduce the tumor burden and control disease progression in patients with relapsed or refractory DLBCL.

Monjuvi Side Effects and Warnings

Like all medications, Monjuvi can cause side effects. Patients receiving Monjuvi side effects and warnings should be aware of both common and potentially serious adverse reactions. It is crucial to discuss any concerns or symptoms with a healthcare provider immediately.

Common side effects reported with Monjuvi include:

• Fatigue or weakness
• Diarrhea
• Cough
• Fever
• Peripheral edema (swelling in the hands or feet)
• Decreased appetite
• Nausea
• Upper respiratory tract infection

More serious warnings associated with Monjuvi include myelosuppression, which is a decrease in bone marrow activity leading to low blood cell counts (e.g., neutropenia, thrombocytopenia, anemia). Patients may also experience infusion-related reactions, which can range from mild symptoms like fever and chills to more severe reactions requiring medical intervention. Infections, including serious and opportunistic infections, have also been reported. Regular monitoring of blood counts and close observation during and after infusions are essential to manage these potential risks effectively.